Alphamab Australia

Alphamab Australia is the clinical development subsidiary of Alphamab Oncology, a leading biopharmaceutical company dedicated to the discovery and commercialization of innovative multi-functional biologics for cancer treatment. The company utilizes its proprietary technology platforms, such as the CRIB (Charge Repulsion Improved Bispecific) and CRAM (Charge Repulsion Antibody Mixture), to develop a robust pipeline of bispecific antibodies and antibody-drug conjugates. Its lead product, envafolimab (KN035), is the world's first subcutaneously administered PD-L1 inhibitor approved for commercial use. Other key programs include KN046, a bispecific antibody targeting PD-L1 and CTLA-4, and KN026, a HER2-targeted bispecific antibody. Alphamab Australia specifically facilitates early-stage clinical trials, leveraging the region's efficient regulatory framework to accelerate global drug development.